SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Korswagen H 2002 Canonical and non-canonical Wnt signaling pathways in Caenorhabditis elegans: Variation on a common signaling theme. Bioessays 24: 801810.
  • 2
    Pandur P, Maurus D, Kuhl M 2002 Increasingly complex: New players enter the Wnt signaling network. Bioessays 24: 881884.
  • 3
    Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM, Wang H, Cundy T, Glorieux FH, Lev D, Zacharin M, Oexle K, Marcelino J, Suwairi W, Heeger S, Sabatakos G, Apte S, Adkins WN, Allgrove J, Arslan-Kirchner M, Batch JA, Beighton P, Black GC, Boles RG, Boon LM, Borrone C, Brunner HG, Carle GF, Dallapiccola B, De Paepe A, Floege B, Halfhide ML, Hall B, Hennekam RC, Hirose T, Jans A, Juppner H, Kim CA, Keppler-Noreuil K, Kohlschuetter A, LaCombe D, Lambert M, Lemyre E, Letteboer T, Peltonen L, Ramesar RS, Romanengo M, Somer H, Steichen-Gersdorf E, Steinmann B, Sullivan B, Superti-Furga A, Swoboda W, van den Boogaard MJ, Van Hul W, Vikkula M, Votruba M, Zabel B, Garcia T, Baron R, Olsen BR, Warman ML 2001 LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107: 513523.
  • 4
    Kato M, Patel MS, Levasseur R, Lobov I, Chang BH, Glass DA II, Hartmann C, Li L, Hwang TH, Brayton CF, Lang RA, Karsenty G, Chan L 2002 Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol 157: 303314.
  • 5
    Holmen SL, Giambernardi TA, Zylstra CR, Buckner-Berghuis BD, Resau JH, Hess JF, Glatt V, Bouxsein ML, Ai M, Warman ML, Williams BO 2004 Decreased BMD and limb deformities in mice carrying mutations in both Lrp5 and Lrp6. J Bone Miner Res 19: 20332040.
  • 6
    Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, Wu D, Insogna K, Lifton RP 2002 High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 346: 15131521.
  • 7
    Little RD, Carulli JP, Del Mastro RG, Dupuis J, Osborne M, Folz C, Manning SP, Swain PM, Zhao SC, Eustace B, Lappe MM, Spitzer L, Zweier S, Braunschweiger K, Benchekroun Y, Hu X, Adair R, Chee L, FitzGerald MG, Tulig C, Caruso A, Tzellas N, Bawa A, Franklin B, McGuire S, Nogues X, Gong G, Allen KM, Anisowicz A, Morales AJ, Lomedico PT, Recker SM, Van Eerdewegh P, Recker RR, Johnson ML 2002 A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 70: 1119.
  • 8
    Van Wesenbeeck L, Cleiren E, Gram J, Beals RK, Benichou O, Scopelliti D, Key L, Renton T, Bartels C, Gong Y, Warman ML, De Vernejoul MC, Bollerslev J, Van Hul W 2003 Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. Am J Hum Genet 72: 763771.
  • 9
    Babij P, Zhao W, Small C, Kharode Y, Yaworsky PJ, Bouxsein ML, Reddy PS, Bodine PV, Robinson JA, Bhat B, Marzolf J, Moran RA, Bex F 2003 High bone mass in mice expressing a mutant LRP5 gene. J Bone Miner Res 18: 960974.
  • 10
    Ai M, Holmen SL, Van Hul W, Williams BO, Warman ML 2005 Reduced affinity to and inhibition by DKK1 form a common mechanism by which high bone mass-associated missense mutations in LRP5 affect canonical Wnt signaling. Mol Cell Biol 25: 49464955.
  • 11
    Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy JD Jr 2003 The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349: 24832494.
  • 12
    Jones SE, Jomary C 2002 Secreted Frizzled-related proteins: Searching for relationships and patterns. Bioessays 24: 811820.
  • 13
    Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE, Wu D 2005 Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 280: 1988319887.
  • 14
    Semenov M, Tamai K, He X 2005 SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem 280: 2677026775.
  • 15
    Bodine PV, Zhao W, Kharode YP, Bex FJ, Lambert AJ, Goad MB, Gaur T, Stein GS, Lian JB, Komm BS 2004 The Wnt antagonist secreted frizzled-related protein-1 is a negative regulator of trabecular bone formation in adult mice. Mol Endocrinol 18: 12221237.
  • 16
    Balemans W, Van Hul W 2004 Identification of the disease-causing gene in sclerosteosis–discovery of a novel bone anabolic target? J Musculoskelet Neuronal Interact 4: 139142.
  • 17
    Sun N, Gao Y, Pretorius J, Morony S, Kostteruik PJ, Somonet S, Lacey DL, Sarosi I, Kurahara C, Pastzy C 2003 High bone mineral density in SOST knock-out mice demonstrates functional conservation of osteocyte mediated bone homeostasis in mouse and human. J Bone Miner Res 18: S1: S7.
  • 18
    Glass DA, Bialek P, Ahn JD, Starbuck M, Clevers MSP, Taketo H, Long MM, Mc F, Mahon AP, Lang RA, Karsenty G 2005 Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 8: 751764.
  • 19
    Ferrari SL, Deutsch S, Choudhury U, Chevalley T, Bonjour JP, Dermitzakis ET, Rizzoli R, Antonarakis SE 2004 Polymorphisms in the low-density lipoprotein receptor-related protein 5 (LRP5) gene are associated with variation in vertebral bone mass, vertebral bone size, and stature in whites. Am J Hum Genet 74: 866875.
  • 20
    Glass D, Patel M, Long F, Taketo MM, McMahon A, Karsenty G 2003 Regulation of bone formation by Wnt signaling. J Bone Miner Res 18: S2: S14.
  • 21
    Chan SD, Karpf DB, Fowlkes ME, Hooks M, Bradley MS, Vuong V, Bambino T, Liu MY, Arnaud CD, Strewler GJ, Nissenson RA 1992 Two homologs of the Drosophila polarity gene frizzled (fz) are widely expressed in mammalian tissues. J Biol Chem 267: 2520225207.
  • 22
    Onyia JE, Helvering LM, Gelbert L, Wei T, Huang S, Chen P, Dow ER, Maran A, Zhang M, Lotinun S, Lin X, Halladay DL, Miles RR, Kulkarni NH, Ambrose EM, Ma YL, Frolik CA, Sato M, Bryant HU, Turner RT 2005 Molecular profile of catabolic versus anabolic treatment regimens of parathyroid hormone (PTH) in rat bone: An analysis by DNA microarray. J Cell Biochem 95: 403418.
  • 23
    Kulkarni NH, Halladay DL, Miles RR, Gilbert LM, Frolik CA, Galvin RJ, Martin TJ, Gillespie MT, Onyia JE 2005 Effects of parathyroid hormone on Wnt signaling pathway in bone. J Cell Biochem 95: 11781190.
  • 24
    Andersson N, Lindberg MK, Ohlsson C, Andersson K, Ryberg B 2001 Repeated in vivo determinations of bone mineral density during parathyroid hormone treatment in ovariectomized mice. J Endocrinol 170: 529537.
  • 25
    Dempster D, Cosman F, Parisien M, Shen V, Lindsay R 1993 Anabolic actions of parathyroid hormone on bone. Endocr Rev 14: 690709.
  • 26
    Sato M, Westmore M, Clendenon J, Smith S, Hannum B, Zeng GQ, Brommage R, Turner CH 2000 Three-dimensional modeling of the effects of parathyroid hormone on bone distribution in lumbar vertebrae of ovariectomized cynomolgus macaques. Osteoporos Int 11: 871880.
  • 27
    Wronski TJ, Li M 1998 PTH: Skeletal effects in the ovariectomized rat model for postmenopausal bone loss. Whitfield JF, Morley P (eds.) Anabolic Treatments for Osteoporosis. CRC Press, Boca Raton, FL, USA, 5981.
  • 28
    Rosen CJ, Bilezikian JP 2001 Clinical review 123: Anabolic therapy for osteoporosis. J Clin Endocrinol Metab 86: 957964.
  • 29
    2003 Forteo approved for osteoporosis treatment. FDA Consum 37: 4.
  • 30
    Donoviel DB, Freed DD, Vogel H, Potter DG, Hawkins E, Barrish JP, Mathur BN, Turner CA, Geske R, Montgomery CA, Starbuck M, Brandt M, Gupta A, Ramirez-Solis R, Zambrowicz BP, Powell DR 2001 Proteinuria and perinatal lethality in mice lacking NEPH1, a novel protein with homology to NEPHRIN. Mol Cell Biol 21: 48294836.
  • 31
    Zambrowicz BP, Friedrich GA, Buxton EC, Lilleberg SL, Person C, Sands AT 1998 Disruption and sequence identification of 2,000 genes in mouse embryonic stem cells. Nature 392: 608611.
  • 32
    Zambrowicz BP, Abuin A, Ramirez-Solis R, Richter LJ, Piggott J, Beltrandel Rio H, Buxton EC, Edwards J, Finch RA, Friddle CJ, Gupta A, Hansen G, Hu Y, Huang W, Jaing C, Key BW Jr, Kipp P, Kohlhauff B, Ma ZQ, Markesich D, Payne R, Potter DG, Qian N, Shaw J, Schrick J, Shi ZZ, Sparks MJ, Van Sligtenhorst I, Vogel P, Walke W, Xu N, Zhu Q, Person C, Sands AT 2003 Wnk1 kinase deficiency lowers blood pressure in mice: A gene-trap screen to identify potential targets for therapeutic intervention. Proc Natl Acad Sci USA 100: 1410914114.
  • 33
    Powell DR, Desai U, Sparks MJ, Hansen G, Gay J, Schrick J, Shi ZZ, Hicks J, Vogel P 2005 Rapid development of glomerular injury and renal failure in mice lacking p53R2. Pediatr Nephrol 20: 432440.
  • 34
    Baron R, Vignery A, Neff L, Silverglate A, Santa Maria A 1983 Processing of undecalcified bone specimens for bone histomorphometry. Recker RR (ed.) Bone Histomorphometry: Techniques and Interpretation. CRC Press, Boca Raton, FL, USA, 1335.
  • 35
    Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR 1987 Bone histomorphometry: Standardization of nomenclature, symbols, and units. J Bone Miner Res 2: 595610.
  • 36
    Frost HM 1983 Bone histomorphometry: Analysis of trabecular bone dynamics. Recker RR (ed.) Bone Histomorphometry: Techniques and Interpretation. CRC Press, Boca Raton, FL, USA, 109131.
  • 37
    Clement-Lacroix P, Ai M, Morvan F, Roman-Roman S, Vayssiere B, Belleville C, Estrera K, Warman ML, Baron R, Rawadi G 2005 Lrp5-independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice. Proc Natl Acad Sci USA 102: 1740617411.
  • 38
    Sawakami K, Robling AG, Ai M, Pitner ND, Liu D, Warden SJ, Li J, Maye P, Rowe DW, Duncan RL, Warman ML, Turner CH 2006 The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment. J Biol Chem 281: 2369823711.
  • 39
    Spencer GJ, Utting JC, Etheridge SL, Arnett TR, Genever PG 2006 Wnt signalling in osteoblasts regulates expression of the receptor activator of NF[kappa]B ligand and inhibits osteoclastogenesis in vitro. J Cell Sci 119: 12831296.
  • 40
    Mulholland DJ, Read JT, Rennie PS, Cox ME, Nelson CC 2003 Functional localization and competition between the androgen receptor and T-cell factor for nuclear beta-catenin: A means for inhibition of the Tcf signaling axis. Oncogene 22: 56025613.
  • 41
    Verras M, Brown J, Li X, Nusse R, Sun Z 2004 Wnt3a growth factor induces androgen receptor-mediated transcription and enhances cell growth in human prostate cancer cells. Cancer Res 64: 88608866.
  • 42
    Yang F, Li X, Sharma M, Sasaki CY, Longo DL, Lim B, Sun Z 2002 Linking beta-catenin to androgen-signaling pathway. J Biol Chem 277: 1133611344.
  • 43
    Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O'Brien CA, Manolagas SC, Jilka RL 2005 Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: A novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 146: 45774583.
  • 44
    Keller H, Kneissel M 2005 SOST is a target gene for PTH in bone. Bone 37: 148158.
  • 45
    Zhou H, Iida-Klein A, Lu SS, Ducayen-Knowles M, Levine LR, Dempster DW, Lindsay R 2003 Anabolic action of parathyroid hormone on cortical and cancellous bone differs between axial and appendicular skeletal sites in mice. Bone 32: 513520.
  • 46
    Bouxsein ML, Pierroz DD, Glatt V, Goddard DS, Cavat F, Rizzoli R, Ferrari SL 2005 beta-Arrestin2 regulates the differential response of cortical and trabecular bone to intermittent PTH in female mice. J Bone Miner Res 20: 635643.
  • 47
    Iida-Klein A, Zhou H, Lu SS, Levine LR, Ducayen-Knowles M, Dempster DW, Nieves J, Lindsay R 2002 Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice. J Bone Miner Res 17: 808816.
  • 48
    Pierroz DD, Bouxsein ML, Rizzoli R, Ferrari SL 2006 Combined treatment with a beta-blocker and intermittent PTH improves bone mass and microarchitecture in ovariectomized mice. Bone 39: 260267.
  • 49
    Zeng GQ, Cole HW, Smith SJ, Bryant HU, Sato M 1998 Bone effects in mice of ovariectomy and recombinant human PTH (1-34) are highly strain dependent. Bone 23(Suppl 5): S448.
  • 50
    Sakai A, Sakata T, Ikeda S, Uchida S, Okazaki Y, Norimura T, Hori M, Nakamura T 1999 Intermittant administration of human parathyroid hormone (1-34) prevents immobilization-related bone loss by regulating bone marrow capacity for bone cells in ddY mice. J Bone Miner Res 14: 16911699.
  • 51
    Alexander JM, Bab I, Fish S, Muller R, Uchiyama T, Gronowicz G, Nahounou M, Zhao Q, White DW, Chorev M, Gazit D, Rosenblatt M 2001 Human parathyroid hormone 1-34 reverses bone loss in ovariectomized mice. J Bone Miner Res 16: 16651673.
  • 52
    Hurley MM, Okada Y, Xiao L, Tanaka Y, Ito M, Okimoto N, Nakamura T, Rosen CJ, Doetschman T, Coffin JD 2006 Impaired bone anabolic response to parathyroid hormone in Fgf2−/− and Fgf2+/− mice. Biochem Biophys Res Commun 341: 989994.
  • 53
    Iida-Klein A, Hughes C, Lu SS, Moreno A, Shen V, Dempster DW, Cosman F, Lindsay R 2006 Effects of cyclic versus daily hPTH(1-34) regimens on bone strength in association with BMD, biochemical markers, and bone structure in mice. J Bone Miner Res 21: 274282.
  • 54
    Knopp E, Troiano N, Bouxsein M, Sun BH, Lostritto K, Gundberg C, Dziura J, Insogna K 2005 The effect of aging on the skeletal response to intermittent treatment with parathyroid hormone. Endocrinology 146: 19831990.
  • 55
    Zacharin M, Cundy T 2000 Osteoporosis pseudoglioma syndrome: Treatment of spinal osteoporosis with intravenous bisphosphonates. J Pediatr 137: 410415.